The 1989 Nobel prize winner in Chemistry Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function.
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Interleukin-based therapy for Human Cancer: Interleukin-1α (IL-1α) suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene. Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. Together, this study suggests that pharmacological formulations encompassing “IL-1α or its activators” can be used to treat human tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Interleukin-based therapy for Human Cancer: Interleukin-1α (IL-1α) suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 7/April/2014, 7.36 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How IL-1α suppresses the expression of TPP1